The Studio at Kendall Square

In a wide-ranging discussion, Dr. Singh and Dr. Andtbacka reflect on the success of the immunotherapy field and the cancer centers that helped develop the new medicines, career leaps to industry, dea…

Yossef Baidi and Fang Xie describe how getting involved in the club has benefited them, and the idea behind their new podcast (George Church and Peter Kolchinsky have already been guests). Plus, the …

She discusses the report and specifics on NIH funding, VC investment, jobs, biotech clusters within Massachusetts, and more.

They explain the size and depth of the cuts, and how it will affect research on both respiratory and non-respiratory conditions. Plus, what it means for global competitiveness for the United States g…

Lisa and Richard describe the unmet need for frontotemporal dementia and their partnership on AVB-101, which is administered directly to the thalamus. They describe the unique perspectives and skill …

Interviewed by fellow veteran Jim Barsoum, Dr. Krieg shares multi-decade learnings from his previous companies Coley Pharmaceutical Group and Checkmate Pharmaceuticals, and describes how Zola builds …

Interviewed by Andy Plump, President of R&D at Takeda, Dr. Zerhouni discusses the rationale for multispecifics and the science behind them. They also discuss the differences between pharma and biotec…

Ram Aiyar, President & CEO of Korro Bio, and Uli Stilz, Head of Novo Nordisk's Bio Innovation Hub in Kendall Square, share their backgrounds and the scope of their work today. They discuss their RNA …

Devan Shah, Founder & CEO of RNAV8 Bio, and Namita Bisaria, Head of Research, Strategy, and Operations at AIRNA, discusses approaches to RNA they are excited about this year, companies that have impr…

In a discussion with gene editing technology expert TJ Cradick, Scientific Citizenship Initiative Co-Founder and Co-Director Daniel Pomeroy describes the history and goal of this non-profit organizat…

Dion Foundation Co-Founder and President Courtney Dion discusses with Atamyo Therapeutics CEO Stéphane Degove the many ways that patient advocate groups can support the work that biotech companies do…

They discuss Odyssey's work, the investments it has made regarding in silico and AI/ML tools, the unique value of the Boston biotech ecosystem, and keys to successful collaborations.

Biotech industry veteran Harvery Berger talks about his company's job at hand to translate the science of ferroptosis into therapies. Plus, a warning about the currently very difficult funding enviro…

Cigall Kadoch, associate professor and HHMI Investigator, Dana-Farber Cancer Institute and Harvard Medical School, and scientific founder of Foghorn Therapeutics (NASDAQ: FHTX), interviews Rick Young…

Lauren Celano, a board member of the National Tay-Sachs & Allied Diseases Association, interviews Lee Greenwood about his family's experience with Canavan disease and how patient organizations and in…

For this high-tech emerging field within biotech, it is important to get safety right. They discuss the keys to understanding the possible range of edits, choosing the right assay, assessing and repo…

Dan Mandell, Co-Founder and CEO of GRO Biosciences, interviews professor Church about the Genomically Recoded Organisms (GRO) platform that Dan spun out of his lab, asks him what technologies he is w…

Dr. Excoffon describes her academic experience that led her to the field and Spirovant Sciences, discusses interesting data from last month’s North American Cystic Fibrosis Conference, and then highl…

Dr. Su and Dr. Hege talk about solving the cell therapy solid tumor challenge, the latest in bi-specifics, her recent hike of the Pacific Crest Trail for charity, and a preview of the upcoming SITC a…